Nanotechnology enabled targeting of p53 deficiency in human cancer View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2016-2021

FUNDING AMOUNT

1084590 USD

ABSTRACT

Project Summary/Abstract There has been little change in mortality rate of human colorectal cancer (CRC) in the past decades and the treatment options available for CRC are still very limited today. In CRC and most other human cancers, the tumor suppressor TP53 gene is frequently inactivated by mutation or deletion. Consequently, tremendous effort has been made to restore the p53 activity for cancer therapy. However, no p53-based therapy has been successfully translated into clinical cancer treatment due to the complexity of p53 signaling. Therefore, instead of restoring the p53 activity, identifying vulnerabilities conferred by TP53 deletion or mutation is a novel strategy for fighting against the p53 deficiency in human cancer. In a recent study published in Nature, we confirmed that genomic deletion of TP53 is frequently accompanied by the partial loss of neighboring essential genes and cancer cells with hemizygous TP53 deletion are remarkably vulnerable to further suppression of such neighboring essential genes. We revealed that POLR2A is such an essential gene that is often partially co-deleted with TP53 in human cancers. Such hemizygous loss of TP53/POLR2A occurs in 53, 60, and 41% of colorectal, breast, and pancreatic cancers, respectively. The POLR2A activity is specifically inhibited by ?-Amanitin (Ama), a cyclic peptide of 8 amino acids found in the mushroom Amanita phalloides. We demonstrate that low doses of Ama conjugated with anti-epithelial cell adhesion molecule (EpCAM) antibody for targeting CRC can result in much enhanced tumor regression in murine models of human CRC with hemizygous deletion of POLR2A without evident systemic toxicity. However, a small fraction of CRC cells are found to be resistant to Ama in a dose-dependent manner. These drug-resistant cells are often called cancer stem-like cells (CSCs) or tumor initiating cells (TICs). A common feature of the CSCs in many cancers (e.g., CRC together with breast and pancreatic cancers) is that they overexpress the variant CD44. Our preliminary data show that the Ama-resistant CRC cells are indeed enriched with CD44, but not EpCAM. Moreover, our studies show that human breast and prostate CSCs can be effectively destroyed in vitro and in vivo using anticancer agent-laden nanoparticles that target the variant CD44 (but not the normal or non-variant CD44 on normal stem cells) with no evident systemic toxicity. Here, we hypothesize that targeted delivery of Ama and/or clinically used anticancer drugs to the variant CD44+ cancer cells with nanoparticles can overcome their drug resistance. We will test this hypothesis with two specific aims: 1, to determine the mechanisms of resistance to the Ama-based POLR2A-targted therapy of human CRCs with hemizygous loss of TP53 and 2, to determine if the combined therapy of Ama and clinically used anticancer drugs co-delivered with the variant CD44-targeting nanoparticles can overcome the drug resistance of human CRCs. It is expected that this project may result in a novel approach to targeting TP53 and could have a major impact on the treatment of colorectal and other cancers harboring TP53 deficiency. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9696179

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "1084590"
    }, 
    "description": "Project Summary/Abstract There has been little change in mortality rate of human colorectal cancer (CRC) in the past decades and the treatment options available for CRC are still very limited today. In CRC and most other human cancers, the tumor suppressor TP53 gene is frequently inactivated by mutation or deletion. Consequently, tremendous effort has been made to restore the p53 activity for cancer therapy. However, no p53-based therapy has been successfully translated into clinical cancer treatment due to the complexity of p53 signaling. Therefore, instead of restoring the p53 activity, identifying vulnerabilities conferred by TP53 deletion or mutation is a novel strategy for fighting against the p53 deficiency in human cancer. In a recent study published in Nature, we confirmed that genomic deletion of TP53 is frequently accompanied by the partial loss of neighboring essential genes and cancer cells with hemizygous TP53 deletion are remarkably vulnerable to further suppression of such neighboring essential genes. We revealed that POLR2A is such an essential gene that is often partially co-deleted with TP53 in human cancers. Such hemizygous loss of TP53/POLR2A occurs in 53, 60, and 41% of colorectal, breast, and pancreatic cancers, respectively. The POLR2A activity is specifically inhibited by ?-Amanitin (Ama), a cyclic peptide of 8 amino acids found in the mushroom Amanita phalloides. We demonstrate that low doses of Ama conjugated with anti-epithelial cell adhesion molecule (EpCAM) antibody for targeting CRC can result in much enhanced tumor regression in murine models of human CRC with hemizygous deletion of POLR2A without evident systemic toxicity. However, a small fraction of CRC cells are found to be resistant to Ama in a dose-dependent manner. These drug-resistant cells are often called cancer stem-like cells (CSCs) or tumor initiating cells (TICs). A common feature of the CSCs in many cancers (e.g., CRC together with breast and pancreatic cancers) is that they overexpress the variant CD44. Our preliminary data show that the Ama-resistant CRC cells are indeed enriched with CD44, but not EpCAM. Moreover, our studies show that human breast and prostate CSCs can be effectively destroyed in vitro and in vivo using anticancer agent-laden nanoparticles that target the variant CD44 (but not the normal or non-variant CD44 on normal stem cells) with no evident systemic toxicity. Here, we hypothesize that targeted delivery of Ama and/or clinically used anticancer drugs to the variant CD44+ cancer cells with nanoparticles can overcome their drug resistance. We will test this hypothesis with two specific aims: 1, to determine the mechanisms of resistance to the Ama-based POLR2A-targted therapy of human CRCs with hemizygous loss of TP53 and 2, to determine if the combined therapy of Ama and clinically used anticancer drugs co-delivered with the variant CD44-targeting nanoparticles can overcome the drug resistance of human CRCs. It is expected that this project may result in a novel approach to targeting TP53 and could have a major impact on the treatment of colorectal and other cancers harboring TP53 deficiency.", 
    "endDate": "2021-06-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.48336.3a", 
      "type": "Organization"
    }, 
    "id": "sg:grant.5476206", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "5476206"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01CA206366"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "study", 
      "normal stem cells", 
      "project", 
      "further suppression", 
      "vivo", 
      "TICS", 
      "hemizygous TP53 deletions", 
      "targeting", 
      "Such hemizygous loss", 
      "most other human cancers", 
      "small fraction", 
      "anticancer agent-laden nanoparticles", 
      "novel approach", 
      "amino acids", 
      "deletion", 
      "dose-dependent manner", 
      "vitro", 
      "cyclic peptides", 
      "abstract", 
      "treatment options", 
      "vulnerability", 
      "murine model", 
      "nanotechnology", 
      "breast", 
      "p53", 
      "human CRC", 
      "anticancer drugs", 
      "variant CD44+ cancer cells", 
      "tremendous efforts", 
      "TP53", 
      "clinical cancer treatment", 
      "mushroom Amanita", 
      "colorectal", 
      "POLR2A activity", 
      "tumor regression", 
      "major impact", 
      "cancer stem-like cells", 
      "TP53 deficiency", 
      "hemizygous loss", 
      "common feature", 
      "p53 activity", 
      "tumor", 
      "prostate CSCs", 
      "cancer therapy", 
      "specific aim", 
      "hemizygous deletion", 
      "Ama-resistant CRC cells", 
      "preliminary data", 
      "past decade", 
      "many cancers", 
      "human cancers", 
      "variants", 
      "CRC cells", 
      "low doses", 
      "nature", 
      "variant CD44", 
      "complexity", 
      "limited today", 
      "tumor suppressor TP53 gene", 
      "essential genes", 
      "treatment", 
      "anti-epithelial cell adhesion molecule", 
      "Recent studies", 
      "delivery", 
      "mortality rate", 
      "CD44", 
      "resistance", 
      "-amanitin", 
      "mechanism", 
      "p53 deficiency", 
      "POLR2A", 
      "mutations", 
      "genomic deletion", 
      "other cancers", 
      "nanoparticles", 
      "project summaries", 
      "such neighboring", 
      "evident systemic toxicity", 
      "therapy", 
      "cells", 
      "TP53/POLR2A", 
      "hypothesis", 
      "EpCAM", 
      "human colorectal cancer", 
      "AMA", 
      "human breast", 
      "drug-resistant cells", 
      "non-variant CD44", 
      "pancreatic cancer", 
      "novel strategy", 
      "partial loss", 
      "TP53 deletion", 
      "antibodies", 
      "cancer cells", 
      "little change", 
      "drug resistance"
    ], 
    "name": "Nanotechnology enabled targeting of p53 deficiency in human cancer", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.164295.d", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.164295.d", 
          "name": "UNIV OF MARYLAND, COLLEGE PARK", 
          "type": "Organization"
        }, 
        "familyName": "HE", 
        "givenName": "XIAOMING", 
        "id": "sg:person.016273765117.41", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.016273765117.41", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.5476206"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2019-03-07T12:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_7.xml.gz", 
    "startDate": "2016-07-08T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9696179"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.5476206'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.5476206'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.5476206'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.5476206'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      19 PREDICATES      118 URIs      110 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.5476206 schema:about anzsrc-for:2211
2 schema:amount N7d60b4d1960448f9815d0f59a7aa9a9c
3 schema:description Project Summary/Abstract There has been little change in mortality rate of human colorectal cancer (CRC) in the past decades and the treatment options available for CRC are still very limited today. In CRC and most other human cancers, the tumor suppressor TP53 gene is frequently inactivated by mutation or deletion. Consequently, tremendous effort has been made to restore the p53 activity for cancer therapy. However, no p53-based therapy has been successfully translated into clinical cancer treatment due to the complexity of p53 signaling. Therefore, instead of restoring the p53 activity, identifying vulnerabilities conferred by TP53 deletion or mutation is a novel strategy for fighting against the p53 deficiency in human cancer. In a recent study published in Nature, we confirmed that genomic deletion of TP53 is frequently accompanied by the partial loss of neighboring essential genes and cancer cells with hemizygous TP53 deletion are remarkably vulnerable to further suppression of such neighboring essential genes. We revealed that POLR2A is such an essential gene that is often partially co-deleted with TP53 in human cancers. Such hemizygous loss of TP53/POLR2A occurs in 53, 60, and 41% of colorectal, breast, and pancreatic cancers, respectively. The POLR2A activity is specifically inhibited by ?-Amanitin (Ama), a cyclic peptide of 8 amino acids found in the mushroom Amanita phalloides. We demonstrate that low doses of Ama conjugated with anti-epithelial cell adhesion molecule (EpCAM) antibody for targeting CRC can result in much enhanced tumor regression in murine models of human CRC with hemizygous deletion of POLR2A without evident systemic toxicity. However, a small fraction of CRC cells are found to be resistant to Ama in a dose-dependent manner. These drug-resistant cells are often called cancer stem-like cells (CSCs) or tumor initiating cells (TICs). A common feature of the CSCs in many cancers (e.g., CRC together with breast and pancreatic cancers) is that they overexpress the variant CD44. Our preliminary data show that the Ama-resistant CRC cells are indeed enriched with CD44, but not EpCAM. Moreover, our studies show that human breast and prostate CSCs can be effectively destroyed in vitro and in vivo using anticancer agent-laden nanoparticles that target the variant CD44 (but not the normal or non-variant CD44 on normal stem cells) with no evident systemic toxicity. Here, we hypothesize that targeted delivery of Ama and/or clinically used anticancer drugs to the variant CD44+ cancer cells with nanoparticles can overcome their drug resistance. We will test this hypothesis with two specific aims: 1, to determine the mechanisms of resistance to the Ama-based POLR2A-targted therapy of human CRCs with hemizygous loss of TP53 and 2, to determine if the combined therapy of Ama and clinically used anticancer drugs co-delivered with the variant CD44-targeting nanoparticles can overcome the drug resistance of human CRCs. It is expected that this project may result in a novel approach to targeting TP53 and could have a major impact on the treatment of colorectal and other cancers harboring TP53 deficiency.
4 schema:endDate 2021-06-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.48336.3a
6 schema:identifier N92d2744296854f838a572cef6f908af3
7 Nb1da4152f8104453b0d91d300dbf216e
8 schema:inLanguage en
9 schema:keywords -amanitin
10 AMA
11 Ama-resistant CRC cells
12 CD44
13 CRC cells
14 EpCAM
15 POLR2A
16 POLR2A activity
17 Recent studies
18 Such hemizygous loss
19 TICS
20 TP53
21 TP53 deficiency
22 TP53 deletion
23 TP53/POLR2A
24 abstract
25 amino acids
26 anti-epithelial cell adhesion molecule
27 antibodies
28 anticancer agent-laden nanoparticles
29 anticancer drugs
30 breast
31 cancer cells
32 cancer stem-like cells
33 cancer therapy
34 cells
35 clinical cancer treatment
36 colorectal
37 common feature
38 complexity
39 cyclic peptides
40 deletion
41 delivery
42 dose-dependent manner
43 drug resistance
44 drug-resistant cells
45 essential genes
46 evident systemic toxicity
47 further suppression
48 genomic deletion
49 hemizygous TP53 deletions
50 hemizygous deletion
51 hemizygous loss
52 human CRC
53 human breast
54 human cancers
55 human colorectal cancer
56 hypothesis
57 limited today
58 little change
59 low doses
60 major impact
61 many cancers
62 mechanism
63 mortality rate
64 most other human cancers
65 murine model
66 mushroom Amanita
67 mutations
68 nanoparticles
69 nanotechnology
70 nature
71 non-variant CD44
72 normal stem cells
73 novel approach
74 novel strategy
75 other cancers
76 p53
77 p53 activity
78 p53 deficiency
79 pancreatic cancer
80 partial loss
81 past decade
82 preliminary data
83 project
84 project summaries
85 prostate CSCs
86 resistance
87 small fraction
88 specific aim
89 study
90 such neighboring
91 targeting
92 therapy
93 treatment
94 treatment options
95 tremendous efforts
96 tumor
97 tumor regression
98 tumor suppressor TP53 gene
99 variant CD44
100 variant CD44+ cancer cells
101 variants
102 vitro
103 vivo
104 vulnerability
105 schema:name Nanotechnology enabled targeting of p53 deficiency in human cancer
106 schema:recipient N83aaf1496f694dbab6f1b2b74342dc54
107 sg:person.016273765117.41
108 https://www.grid.ac/institutes/grid.164295.d
109 schema:sameAs https://app.dimensions.ai/details/grant/grant.5476206
110 schema:sdDatePublished 2019-03-07T12:14
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nb9974d8247f14fa0b6a4034e5b252b3d
113 schema:startDate 2016-07-08T00:00:00Z
114 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9696179
115 sgo:license sg:explorer/license/
116 sgo:sdDataset grants
117 rdf:type schema:MonetaryGrant
118 N7d60b4d1960448f9815d0f59a7aa9a9c schema:currency USD
119 schema:value 1084590
120 rdf:type schema:MonetaryAmount
121 N83aaf1496f694dbab6f1b2b74342dc54 schema:member sg:person.016273765117.41
122 schema:roleName PI
123 rdf:type schema:Role
124 N92d2744296854f838a572cef6f908af3 schema:name dimensions_id
125 schema:value 5476206
126 rdf:type schema:PropertyValue
127 Nb1da4152f8104453b0d91d300dbf216e schema:name nih_id
128 schema:value R01CA206366
129 rdf:type schema:PropertyValue
130 Nb9974d8247f14fa0b6a4034e5b252b3d schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
133 rdf:type schema:DefinedTerm
134 sg:person.016273765117.41 schema:affiliation https://www.grid.ac/institutes/grid.164295.d
135 schema:familyName HE
136 schema:givenName XIAOMING
137 rdf:type schema:Person
138 https://www.grid.ac/institutes/grid.164295.d schema:name UNIV OF MARYLAND, COLLEGE PARK
139 rdf:type schema:Organization
140 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...